OTCM
RTSL
Market cap0kUSD
Jul 08, Last price
0.00USD
IPO
-99.96%
Name
Rapid Therapeutic Science Laboratories Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
134.87%
Rev. gr., 5y
%
Revenues
0k
Net income
-183k
L-89.18%
CFO
-1m
L-47.87%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2022‑12 | 2021‑12 | 2020‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||